FINAL RESULTS OF THE BASIL TRIAL (BYPASS VERSUS ANGIOPLASTY IN SEVERE ISCHAEMIA OF THE LEG)

CONTENTS

Volume 51, Number 10S May Supplement 2010

GUEST EDITOR Andrew W. Bradbury, BSc, MD, MBA, FRCSEd

Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial in perspective
Andrew W. Bradbury, BSc, MD, MBA, FRCSEd, on behalf of the BASIL trial Investigators and Participants, Birmingham, United Kingdom

Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: An intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy
Andrew W. Bradbury, BSc, MD, MBA, FRCSEd, Donald J. Adam, MD, FRCSEd, Jocelyn Bell, PhD, John F. Forbes, PhD, F. Gerry R. Fowkes, PhD, FRCPE, Ian Gillespie, MD, FRCR, Charles Vaughan Ruckley, ChM, FRCSEd, CBE, and Gillian M. Raab, PhD, on behalf of the BASIL trial Participants, Birmingham and Edinburgh, United Kingdom

Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: Analysis of amputation free and overall survival by treatment received
Andrew W. Bradbury, BSc, MD, MBA, FRCSEd, Donald J. Adam, MD, FRCSEd, Jocelyn Bell, PhD, John F. Forbes, PhD, F. Gerry R. Fowkes, PhD, FRCPE, Ian Gillespie, MD, FRCR, Charles Vaughan Ruckley, ChM, FRCSEd, CBE, and Gillian M. Raab, PhD, on behalf of the BASIL trial Participants, Birmingham and Edinburgh, United Kingdom

Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: A description of the severity and extent of disease using the Bollinger angiogram scoring method and the TransAtlantic Inter-Society Consensus II classification
Andrew W. Bradbury, BSc, MD, MBA, FRCSEd, Donald J. Adam, MD, FRCSEd, Jocelyn Bell, PhD, John F. Forbes, PhD, F. Gerry R. Fowkes, PhD, FRCPE, Ian Gillespie, MD, FRCR, Charles Vaughan Ruckley, ChM, FRCSEd, CBE, and Gillian M. Raab, PhD, on behalf of the BASIL trial Participants, Birmingham and Edinburgh, United Kingdom
Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: Health-related quality of life outcomes, resource utilization, and cost-effectiveness analysis
John F. Forbes, PhD, Donald J. Adam, MD, FRCSEd, Jocelyn Bell, PhD, F. Gerry R. Fowkes, PhD, FRCPE, Ian Gillespie, MD, FRCR, Gillian M. Raab, PhD, Charles Vaughan Ruckley, ChM, FRCSEd, CBE, and Andrew W. Bradbury, BSc, MD, MBA, FRCSEd, on behalf of the BASIL trial Participants, Edinburgh and Birmingham, United Kingdom

Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: A survival prediction model to facilitate clinical decision making
Andrew W. Bradbury, BSc, MD, MBA, FRCSEd, Donald J. Adam, MD, FRCSEd, Jocelyn Bell, PhD, John F. Forbes, PhD, F. Gerry R. Fowkes, PhD, FRCPE, Ian Gillespie, MD, FRCR, Charles Vaughan Ruckley, ChM, FRCSEd, CBE, and Gillian M. Raab, PhD, on behalf of the BASIL trial Participants, Birmingham and Edinburgh, United Kingdom

Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) and the (hoped for) dawn of evidence-based treatment for advanced limb ischemia
Michael S. Conte, MD, San Francisco, Calif